Clinical Trials Logo
  1. Home
  2. Chronic HBV Infection
  3. NCT05019040

Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of PA1010 in HBV Patients

Chronic HBV Infection Clinical Trial

Official title:
A Phase 1b Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of Multiple Ascending Dose (MAD) of PA1010 Tablets in Chinese Patients With Chronic Hepatitis B Infection

Clinical Trial Summary

The primary objective of this study is to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of multiple ascending dose (MAD) of PA1010 tablets in Chinese adults with Chronic Hepatitis B.

Clinical Trial Description

This is a multicenter, randomized, open-label, controlled, dose-escalation clinical trial, the objective is to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of PA1010 tablets in Chinese patients with Chronic Hepatitis B (CHB). There are three dose groups of PA1010 ( 5 mg, 10 mg, and 20 mg) proposed to be tested sequentially in this study. A total of 36 patients with CHB, either hepatitis B e antigen (HBeAg)-positive (+) or HBeAg-negative (-), are planned to be enrolled in this study and will be stratified by HBeAg status by the ratio of 2: 1, that is, 24 of HBeAg + and 12 of HBeAg- patients. Twelve subjects in each dose group were randomly assigned in a 3: 1 ratio to receive either PA1010 tablets or or tenofovir disoproxil fumarate (TDF) tablets. All patients will be dosed for 28 consecutive days, and the dose-related safety, PK, and antiviral efficacy of PA1010 will be evaluated. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05019040
Study type Interventional
Source Zhejiang Palo Alto Pharmaceuticals, Inc.
Contact
Status Completed
Phase Phase 1/Phase 2
Start date September 17, 2021
Completion date November 18, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT04470388 - A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment Phase 1
Completed NCT01943799 - Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B Phase 2
Recruiting NCT05792761 - A Study on Antiviral Treatment of Chronic Hepatitis B in Children N/A
Completed NCT05468060 - Study of the Safety, Tolerability, Pharmacokinetic Characteristics of PA1010 in Healthy Subjects Phase 1
Completed NCT04008004 - A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2) Phase 1
Active, not recruiting NCT05734807 - A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level Viremia Phase 2
Completed NCT06029634 - Effects of T-bet B Cells in Persistent Virus Control After Discontinuance of NAs in CHB Patients
Completed NCT04147208 - Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection Phase 2
Completed NCT03909191 - Serum HBV RNA Value on Chronic Hepatitis B Virus Infection Manage
Completed NCT03664518 - to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia With Chronic HBV Infection Phase 2
Completed NCT05542979 - A Study to Evaluate the Safety, Tolerability of HH-003 Injection in Participants With Chronic Hepatitis B Virus Infection Phase 1
Active, not recruiting NCT03903796 - Study of the Efficacy and Safety of HS-10234 in Patients With Chronic Hepatitis B Virus Infection Phase 3
Completed NCT05851261 - Study to Evaluate the Safety, Tolerance, Pharmacokinetics Characteristics of PA3670 Tablets in Chinese Healthy Subjects Phase 1